FOXO1 and cancer: Nevertheless, in variety of other cancer miR-27a, miR-96, and miR-182 act as oncomiRs to suppress FOXO1, including renal cell cancer [27], bladder cancer [28], Prostate cancer [29], colorectal cancer [30], thyroid carcinoma [31], ovarian cancer [32], liver cancer [33], gastric cancer [34], adenocarcinoma [35], and cervical cancer [36].